Cytyc Corp., of Boxborough, Mass., named Timothy Krauskopf vice president of regulatory and clinical affairs.

Digital Gene Technologies Inc., of La Jolla, Calif., named David Lo vice president of integrative biology.

Epimmune Inc., of San Diego, named Robert De Vaere vice president, finance and chief financial officer.

Exact Laboratories Inc., of Maynard, Mass., appointed to its board of directors Lance Willsey, founding partner of DCF Capital.

Genomica Corp., of Boulder, Colo., appointed Charles Philipp vice president of marketing.

GenStar Therapeutics, of San Diego, named Lee McCracken president and chief business officer.

ICOS Corp., of Bothell, Wash., named Leonard Blum vice president of marketing.

Idun Pharmaceuticals Inc., of La Jolla, Calif., appointed Al Spada to the new position of vice president of pharmaceutical development.

Immunex Corp., of Seattle, named Thomas Daniel vice president of vascular biology, discovery research, and Barry Labinger vice president of marketing for Enbrel.

Incara Pharmaceuticals Corp., of Research Triangle Park, N.C., named Robert Susick vice president, cell technologies, and Richard Gammans senior vice president, antioxidant therapies.

InKine Pharmaceutical Co. Inc., of Blue Bell, Pa., named James Bergey vice president of business development.

Interleukin Genetics Inc., of San Antonio, Texas, named Fenel Eloi chief operating officer and chief financial officer.

InterMune Pharmaceuticals Inc., of Burlingame, Calif., named John Wulf senior vice president of corporate development, and Karen Starko senior director of clinical research.

Kosan Biosciences Inc., of Hayward, Calif., named Susan Dillon vice president, pharmacological sciences.

KS Biomedix, of London, named Steven Powell chief executive officer.

Matrix Pharmaceutical Inc., of Fremont, Calif., named Jeanette Fritzky vice president of sales and marketing.

Merlin Biosciences Ltd., of London, appointed Sue Foden director of technology, and Bob Dammas chief scientist.

Metabolex Inc., of Hayward, Calif., named Mark Bagnall chief financial officer.

Millennium Pharmaceuticals Inc., of Cambridge, Mass., named to its board of directors Norman Selby, senior officer and head of the Consumer Internet Banking Group at Citigroup. It also named Susan Ward senior vice president, strategy leadership.

NeoTherapeutics Inc., of Irvine, Calif., appointed Mark Foreman senior director of research.

Orchid BioSciences Inc., of Princeton, N.J., appointed Christopher Ashton vice president and managing director of European operations; Russell Granzow vice president, marketing, sales and business development; and Scott Rakestraw executive director of therapeutics business development.

Oxxon Pharmaccines Ltd., of Oxford, UK, appointed Roger Brimblecombe non-executive chairman.

Palatin Technologies Inc., of Princeton, N.J., appointed Carl Spana interim CEO and president. John K.A. Prendergast was named interim non-executive chairman of the board. Spana already serves as executive vice president and chief technology officer.

Panacea Pharmaceuticals Inc., of Rockville, Md., named Alan Deutch vice president for business development and director of the diagnostic division.

PolyMASC Pharmaceuticals plc, of London, hired James Green as commercial development director.

Procyon BioPharma Inc., of Montreal, named Edward Yeats secretary-treasurer and chief financial officer; Salam Kadhim senior research director, oncology; and Seema Garde senior research scientist. It also appointed to its scientific advisory board Alan Wolffe, senior vice president and chief scientific officer of Sangamo BioSciences Inc.

Rosetta Inpharmatics Inc., of Kirkland, Wash., appointed Mark Boguski senior vice president of research and development.

Salix Pharmaceuticals Ltd., of Raleigh, N.C., named Carolyn Logan senior vice president, sales and marketing.

No Comments